Key result
Elevated GDF-15 is linked to atrial remodeling and independently predicts AF recurrence and thromboembolism.
Why the study?
Cardiac arrhythmias, especially atrial fibrillation, require improved risk stratification beyond traditional demographic factors, motivating exploration of GDF-15 as a biomarker.
Does GDF-15 assessment improve risk stratification for arrhythmogenesis and thromboembolic events in patients with cardiac arrhythmias?
Does GDF-15 assessment improve risk stratification for arrhythmogenesis and thromboembolic events in patients with cardiac arrhythmias?
GDF-15 shows potential as a biomarker for risk stratification in atrial fibrillation, predicting recurrence and thromboembolic events, though assay inconsistency limits current clinical use.
Answers are grounded in this paper and cite their sources.
Supports GDF-15 for AF risk stratification beyond demographics; leaves open prospective validation before clinical adoption.
Cardiac arrhythmias, particularly atrial fibrillation (AF), are an emerging clinical problem and need risk stratification beyond the traditional demographic factors. Growth Differentiation Factor-15 (GDF-15), a stress responsive cytokine of the transforming growth factor-beta (TGF-β) superfamily, has been explored as a biomarker of systemic inflammation, oxidative stress and extracellular matrix remodeling. The narrative review summarizes the molecular, diagnostic and prognostic role of GDF-15 in arrhythmogenesis. Higher levels of GDF-15 are associated with the degree of atrial fibrosis and structural remodeling in AF independently predicting recurrence of the disease and thromboembolic events. Its value in forecasting initial ventricular arrhythmias, however, is sometimes clouded by the severity of chronic heart failure. Mechanistically, GDF-15 connects cellular stress pathways with pro-fibrotic structural changes that favor electrical instability. GDF-15 improves multi-marker risk algorithms such as the ABC-AF score, however inconsistency in immunoassays and reliance on observational data limit its use in ordinary clinical practice. Future multi-omics studies and established reference cut-offs are needed to advance GDF-15 from an epidemiological marker to a specific clinical risk modifier.
No takes yet. Share an insight, caveat, or question.
Chowdhury et al. (2026) conducted a review in Cardiac arrhythmias, particularly atrial fibrillation (AF). GDF-15 was evaluated. Higher levels of GDF-15 are associated with atrial fibrosis and structural remodeling in AF, independently predicting disease recurrence and thromboembolic events.
Synapse has enriched 10 related papers. Consider them for comparative context: